Finding Maximum Tolerated Dose in Phase I Oncology Clinical Trials with Bayesian Methods

被引：0
|
作者：
Sapi, Johanna [1 ,2 ]
机构：
[1] Obuda Univ, Biomat & Appl Artificial Intelligence Inst, John von Neumann Fac Informat, Becsi Ut 96-B, H-1034 Budapest, Hungary
[2] Obuda Univ, Univ Res & Innovat Ctr, Physiol Controls Res Ctr, Becsi Ut 96-B, H-1034 Budapest, Hungary
来源：
ACTA POLYTECHNICA HUNGARICA | 2024年 / 21卷 / 06期
关键词：
maximum tolerated dose (MTD); dose-limiting toxicity (DLT); Continual Reassessment Method (CRM); Time-To-Event Continual Reassessment Method (TITE- CRM); copula regression model; logistic regression model; delayed toxicities; late-onset toxicity model; CONTINUAL REASSESSMENT; DESIGN; TOXICITY; COMBINATIONS; AGENT;
D O I：
暂无
中图分类号：
T [工业技术];
学科分类号：
08 ;
摘要：
Maximum tolerated dose (MTD) is a maximal amount of drug or radiation resulting relatively acceptable dose-limiting toxicity (DLT). Accurate value of MTD should be found in Phase I trials in order to create the possibility to conduct successful Phase II (pilot efficacy and safety evaluation) and Phase III (comparative efficacy) trials. The aim of this paper is to review the difficulties of the dose-finding methods including multi-agent problems and late-onset toxicities, and to discuss Bayesian adaptive dose-finding methods which can handle these issues.
引用
收藏
页码：129 / 145
页数：17
相关论文
共 50 条
  • [31] A dose-schedule finding design for phase I-II clinical trials
    Guo, Beibei
    Li, Yisheng
    Yuan, Ying
    JOURNAL OF THE ROYAL STATISTICAL SOCIETY SERIES C-APPLIED STATISTICS, 2016, 65 (02) : 259 - 272
  • [32] A Bayesian adaptive dose-finding algorithm for balancing individual- and population-level ethics in Phase I clinical trials
    Kim, Steven B.
    Gillen, Daniel L.
    SEQUENTIAL ANALYSIS-DESIGN METHODS AND APPLICATIONS, 2016, 35 (04): : 423 - 439
  • [33] Optimal dose escalation methods using deep reinforcement learning in phase I oncology trials
    Matsuura, Kentaro
    Sakamaki, Kentaro
    Honda, Junya
    Sozu, Takashi
    JOURNAL OF BIOPHARMACEUTICAL STATISTICS, 2023, 33 (05) : 639 - 652
  • [34] Comparison Among Modified Continual Reassessment Methods with Different Dose Allocation Methods for Phase I Clinical Trials
    Xiao, Jiacheng
    Zhang, Weijia
    Li, Rong
    Wen, Conghua
    MATHEMATICS, 2025, 13 (05)
  • [35] Bayesian modeling of a bivariate toxicity outcome for early phase oncology trials evaluating dose regimens
    Gerard, Emma
    Zohar, Sarah
    Lorenzato, Christelle
    Ursino, Moreno
    Riviere, Marie-Karelle
    STATISTICS IN MEDICINE, 2021, 40 (23) : 5096 - 5114
  • [36] Increasing complexity in oncology phase I clinical trials
    Malik, Laeeq
    Lu, David
    INVESTIGATIONAL NEW DRUGS, 2019, 37 (03) : 519 - 523
  • [37] Identifying a maximum tolerated contour in two-dimensional dose finding
    Wages, Nolan A.
    STATISTICS IN MEDICINE, 2017, 36 (02) : 242 - 253
  • [38] Dose individualization and variable selection by using the Bayesian lasso in early phase dose finding trials
    Kakurai, Yasuyuki
    Kaneko, Shuhei
    Hamada, Chikuma
    Hirakawa, Akihiro
    JOURNAL OF THE ROYAL STATISTICAL SOCIETY SERIES C-APPLIED STATISTICS, 2019, 68 (02) : 445 - 460
  • [39] Novel Statistical Designs for Phase I/II and Phase II Clinical Trials With Dose-Finding Objectives
    Sverdlov, Oleksandr
    Wong, Weng Kee
    THERAPEUTIC INNOVATION & REGULATORY SCIENCE, 2014, 48 (05) : 601 - 612
  • [40] Maximum tolerated dose: clinical endpoint for a bygone era?
    Takimoto, Chris H.
    TARGETED ONCOLOGY, 2009, 4 (02) : 143 - 147
12345